Golkor Inc (GKOR)

[usafa]

From their year-end message:

Above all, we thank our clients – both recent and long-term, U.S. and foreign based – for their confidence in our knowledge of Wall Street and our well earned reputation for integrity, insight and judgment. In 2011, we will enter our seventh year of advising NeoStem, Inc. (Amex:NBS), which is poised to benefit from a pending political sea-change for stem cell-based medicine. Throughout 2010, we worked closely with a number of multinational companies, including Bark Group Inc. (OTCBB: BKPG), an innovative integrated advertising and performance-based marketing company with a multi-national client base, as it reorganized, reduced its debt by $9 million, and positioned itself for profitability and growth in 2011. More recently, we were engaged by several exciting companies serving a wide range of markets. Among them are Helix BioPharma Corporation (NYSE Amex, TSX, FSE: HBP), a Canada-based clinical stage company developing innovative products for the treatment of cancer and precancerous diseases; Tongxin International, Ltd. (TXIC: PK), a China-based manufacturer of engineered vehicle body structures (EVBS); and Propanc, Inc., a private Australian clinical-stage biopharmaceutical company focused on developing new cancer treatments for high-risk patients requiring long-term maintenance following surgery, which will shortly seek listing on a U.S. exchange.